A 99mTc-labeled dual-domain cytokine ligand for imaging of inflammation

Nuclear Medicine and Biology

Volumn 38, Issue 6, 2011, Pages 795-805

  Liu, Zhonglin ^a   wyffels, Leonie ^a   Barber, Christy ^a   Hui, Mizhou M ^b   Woolfenden, James M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b AmProtein Inc   (United States)

Author keywords

99mTc; Inflammation; Interleukin 1; Interleukin 18; SPECT

Indexed keywords

2 IMINOTHIOLANE; FC RECEPTOR; INDIUM 111; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 18 BINDING PROTEIN FC RECEPTOR INTERLEUKIN 18 RECEPTOR BLOCKING AGENT TC 99 M; INTERLEUKIN 1BETA; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG UPTAKE; EAR DISEASE; EAR EDEMA; HEART MUSCLE ISCHEMIA; IMAGE ANALYSIS; IN VITRO STUDY; INFLAMMATION; ISOTOPE LABELING; LIGAND BINDING; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN DOMAIN; PROTEIN PURIFICATION; RAT; REPERFUSION INJURY;

ANIMALS; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-18; INTERLEUKIN-1BETA; LEUKOCYTES; LIGANDS; MALE; MICE; MOLECULAR IMAGING; ORGANOTECHNETIUM COMPOUNDS; RATS; SKIN DISEASES; TETRADECANOYLPHORBOL ACETATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 80051678348     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.02.012     Document Type: Article

References (64)

1. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
2. Dinarello C.A. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 2006, 83:447S-455S.
3. Eisenberg S.P., Evans R.J., Arend W.P., Verderber E., Brewer M.T., Hannum C.H., et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990, 343:341-346.
4. Bresnihan B. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. BioDrugs 2001, 15:87-97.
5. Efthimiou P., Markenson J.A. Role of biological agents in immune-mediated inflammatory diseases. South Med J 2005, 98:192-204.
6. Thompson R.C., Dripps D.J., Eisenberg S.P. Interleukin-1 receptor antagonist (IL-1ra) as a probe and as a treatment for IL-1 mediated disease. Int J Immunopharmacol 1992, 14:475-480.
7. Lewis A.M., Varghese S., Xu H., Alexander H.R. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006, 4:48.
8. Sims J., Towne J., Blumberg H. 11 IL-1 family members in inflammatory skin disease. Ernst Schering Res Found Workshop 2006, 187-191.
9. Sims J.E. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 2002, 14:117-122.
10. Chandrasekar B., Colston J.T., de la Rosa S.D., Rao P.P., Freeman G.L. TNF-alpha and H2O2 induce IL-18 and IL-18R beta expression in cardiomyocytes via NF-kappa B activation. Biochem Biophys Res Commun 2003, 303:1152-1158.
11. Dinarello C.A. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999, 103:11-24.
12. Nakamura K., Okamura H., Wada M., Nagata K., Tamura T. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun 1989, 57:590-595.
13. Puren A.J., Fantuzzi G., Gu Y., Su M.S., Dinarello C.A. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998, 101:711-721.
14. Kato Z., Jee J., Shikano H., Mishima M., Ohki I., Ohnishi H., et al. The structure and binding mode of interleukin-18. Nat Struct Biol 2003, 10:966-971.
15. Azam T., Novick D., Bufler P., Yoon D.Y., Rubinstein M., Dinarello C.A., et al. Identification of a critical Ig-like domain in IL-18 receptor alpha and characterization of a functional IL-18 receptor complex. J Immunol 2003, 171:6574-6580.
16. Novick D., Kim S.H., Fantuzzi G., Reznikov L.L., Dinarello C.A., Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999, 10:127-136.
17. Novick D., Schwartsburd B., Pinkus R., Suissa D., Belzer I., Sthoeger Z., et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 2001, 14:334-342.
18. Aizawa Y., Akita K., Taniai M., Torigoe K., Mori T., Nishida Y., et al. Cloning and expression of interleukin-18 binding protein. FEBS Lett 1999, 445:338-342.
19. Cain B.S., Meldrum D.R., Dinarello C.A., Meng X., Joo K.S., Banerjee A., et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 1999, 27:1309-1318.
20. Horton W.E., Udo I., Precht P., Balakir R., Hasty K. Cytokine inducible matrix metalloproteinase expression in immortalized rat chondrocytes is independent of nitric oxide stimulation. In Vitro Cell Dev Biol Anim 1998, 34:378-384.
21. Di Girolamo N., Lloyd A., McCluskey P., Filipic M., Wakefield D. Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. Am J Pathol 1997, 150:653-666.
22. Dinarello C.A. Novel targets for interleukin 18 binding protein. Ann Rheum Dis 2001, 60(Suppl 3):iii18-24.
23. Woldbaek P.R., Tonnessen T., Henriksen U.L., Florholmen G., Lunde P.K., Lyberg T., et al. Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc Res 2003, 59:122-131.
24. Tesic M., Sheldon K.M., Ballinger J.R., Boxen I. Labelling small quantities of monoclonal antibodies and their F(ab')2 fragments with technetium-99 m. Nucl Med Biol 1995, 22:451-457.
25. 99mTc-labeled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction. J Nucl Med 2006, 47:1367-1374.
26. 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies. Methods Find Exp Clin Pharmacol 2002, 24:653-660.
27. Williams J.H., Moser K.M., Ulich T., Cairo M.S. Harvesting the noncirculating pool of polymorphonuclear leukocytes in rats by hetastarch exchange transfusion (HET): yield and functional assessment. J Leukoc Biol 1987, 42:455-462.
28. Issekutz A.C., Nakazato S., Issekutz T.B. Differential roles of VLA-4(CD49d/CD29) and LFA-1(CD11a/CD18) integrins and E- and P-selectin during developing and established active or adoptively transferred adjuvant arthritis in the rat. Immunol Cell Biol 2003, 81:397-408.
29. Sugawara T., Miyamoto M., Takayama S., Kato M. Separation of neutrophils from blood in human and laboratory animals and comparison of the chemotaxis. J Pharmacol Toxicol Methods 1995, 33:91-100.
30. Kim E.J., Park H., Kim J., Park J.H. 3,3′-Diindolylmethane suppresses 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and tumor promotion in mouse skin via the downregulation of inflammatory mediators. Mol Carcinog 2010, 49:672-683.
31. Updyke L.W., Yoon H.L., Chuthaputti A., Pfeifer R.W., Yim G.K. Induction of interleukin-1 and tumor necrosis factor by 12-O-tetradecanoylphorbol-13-acetate in phorbol ester-sensitive (SENCAR) and resistant (B6C3F1) mice. Carcinogenesis 1989, 10:1107-1111.
32. Cao Q., Cai W., Li Z.B., Chen K., He L., Li H.C., et al. PET imaging of acute and chronic inflammation in living mice. Eur J Nucl Med Mol Imaging 2007, 34:1832-1842.
33. Jalilian A.R., Bineshmarvasti M., Sardari S. Application of radioisotopes in inflammation. Curr Med Chem 2006, 13:959-965.
34. Villanueva FS, Wagner WR, Vannan MA, Narula J. Targeted ultrasound imaging using microbubbles. Cardiol Clin 2004;22:283-98, vii.
35. Jaffer F.A., Weissleder R. Seeing within: molecular imaging of the cardiovascular system. Circ Res 2004, 94:433-445.
36. 111In-oxine-labeled leukocytes for detection of infection. Radiology 2006, 238:978-987.
37. 99mTc-hexamethylpropylene-amineoxime for labelling leucocytes and imaging inflammation. Lancet 1986, 2:946-949.
38. Peters A.M., Saverymuttu S.H. The value of indium-labelled leucocytes in clinical practice. Blood Rev 1987, 1:65-76.
39. Peters A.M. Development of radiolabelled white cell scanning. Scand J Gastroenterol Suppl 1994, 203:28-31.
40. 99mTc-RP517, a new leukotriene B4 receptor antagonist that preferentially labels neutrophils in vivo. Circulation 2002, 106:592-598.
41. 111In-LTB4 antagonist is based on in vivo labeling of granulocytes. J Nucl Med 2005, 46:786-793.
42. 99mTc-labeled LTB4 antagonist. J Nucl Med 2005, 46:1546-1551.
43. Faggioni R., Cattley R.C., Guo J., Flores S., Brown H., Qi M., et al. IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J Immunol 2001, 167:5913-5920.
44. Sivakumar P.V., Westrich G.M., Kanaly S., Garka K., Born T.L., Derry J.M., et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 2002, 50:812-820.
45. Schultz M.J., Knapp S., Florquin S., Pater J., Takeda K., Akira S., et al. Interleukin-18 impairs the pulmonary host response to Pseudomonas aeruginosa. Infect Immun 2003, 71:1630-1634.
46. Barrera P., van der Laken C.J., Boerman O.C., Oyen W.J., van de Ven M.T., van Lent P.L., et al. Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:870-874.
47. Granowitz E.V., Porat R., Mier J.W., Pribble J.P., Stiles D.M., Bloedow D.C., et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992, 4:353-360.
48. van der Laken C.J., Boerman O.C., Oyen W.J., van de Ven M.T., Claessens R.A., van der Meer J.W., et al. Different behaviour of radioiodinated human recombinant interleukin-1 and its receptor antagonist in an animal model of infection. Eur J Nucl Med 1996, 23:1531-1535.
49. McCoy R.D., Davidson B.L., Roessler B.J., Huffnagle G.B., Simon R.H. Expression of human interleukin-1 receptor antagonist in mouse lungs using a recombinant adenovirus: effects on vector-induced inflammation. Gene Ther 1995, 2:437-442.
50. Waibel R., Alberto R., Willuda J., Finnern R., Schibli R., Stichelberger A., et al. Stable one-step technetium-99 m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol 1999, 17:897-901.
51. Dripps D.J., Brandhuber B.J., Thompson R.C., Eisenberg S.P. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991, 266:10331-10336.
52. Teige I., Hvid H., Svensson L., Kvist P.H., Kemp K. Regulatory T cells control VEGF-dependent skin inflammation. J Invest Dermatol 2009, 129:1437-1445.
53. Hvid H., Teige I., Kvist P.H., Svensson L., Kemp K. TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. Int Immunol 2008, 20:1097-1106.
54. Deten A., Volz H.C., Briest W., Zimmer H.G. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 2002, 55:329-340.
55. Herskowitz A., Choi S., Ansari A.A., Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995, 146:419-428.
56. Frangogiannis N.G. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 2006, 13:1877-1893.
57. Nian M., Lee P., Khaper N., Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004, 94:1543-1553.
58. Pomerantz B.J., Reznikov L.L., Harken A.H., Dinarello C.A. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A 2001, 98:2871-2876.
59. Malemud C.J. Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging 2010, 27:95-115.
60. Gotthardt M., Bleeker-Rovers C.P., Boerman O.C., Oyen W.J. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med 2010, 51:1937-1949.
61. Joosten L.A., Radstake T.R., Lubberts E., van den Bersselaar L.A., van Riel P.L., van Lent P.L., et al. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2003, 48:339-347.
62. Tak P.P., Bacchi M., Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinetics 2006, 31:109-116.
63. Glaudemans A.W., Dierckx R.A., Kallenberg C.G., Anzola Fuentes K.L. The role of radiolabelled anti-TNFa monoclonal antibodies for diagnostic purposes and therapy evaluation. Q J Nucl Med Mol Imaging 2010, 54:639-653.
64. Saeed M., van Dijke C.F., Mann J.S., Wendland M.F., Rosenau W., Higgins C.B., et al. Histologic confirmation of microvascular hyperpermeability to macromolecular MR contrast medium in reperfused myocardial infarction. J Magn Reson Imaging 1998, 8:561-567.